Several clinical and experimental studies investigated S100B’s potential as a biomarker and its prognostic value in epilepsy since it indicates astroglial damage (Freund et al., 2015; Vizuete et al., 2017; Bulduk et al., 2019). Here, S100B is linked to epilepsy.